19.07.2011 • News

Lonza Begins Tender Offer To Acquire Arch Chemicals

Biocides company Arch Chemicals announced that Lonza's subsidiary, Lonza LG Acquisition Corp., has commenced the previously announced offer to acquire all of the outstanding shares of common stock of Arch Chemicals at a price of $47.20 per share, net to the seller in cash, without interest and less any required withholding of taxes.

The tender offer is scheduled to expire on Aug. 11. The closing of the tender offer is subject to customary terms and conditions. On July 11, Lonza announced its intention to acquire Arch through a tender offer for $47.20 per share in cash. As per the deal, the germs control product maker's enterprise value would be $1.4 billion or about 1.25 billion Swiss francs.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.